ACT

Home/Tag: ACT

Striking improvement in vision in one ACT trial participant

Knoepfler Lab Stem Cell Blog, by Paul Knoepfler ~ May 17, 2013 Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly had 20/400 vision

ACT Announces First Dry AMD Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived RPE Cells

Thursday, August 2, 2012 By: Market Watch Wall Street Journal Patient with Dry Age-Related Macular Degeneration Injected with 100,000 Retinal Pigment Epithelial Cells at Wills Eye Institute in Philadelphia. MARLBOROUGH, Mass., Aug 02, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment

Stem cell scientists take hope from first human trials but see long road ahead

Monday, June 4, 2012 By: Sarah Boseley Much hangs on outcome of first human trials amid funding difficulties, political opposition and public suspicion Health Editor, guardian.co.uk Marcus Hilton sits in front of the TV and stares at the Sky News headlines scrolling along the bottom of the screen. If he moves his head about he

Firm Launches Two Stem Cell Trials Against Blindness

Thursday, July 14, 2011 By: Meredith Wadman, Nature Tests begin on patients with Stargardt's Macular Dystrophy and Age-related Macular Degeneration. Geron made medical history last October, when it treated subject number one in the first-ever trial of a human embryonic stem cell (hESC) therapy, for spinal cord injury. Now, the second and third hESC trials have been

ACT: First Patients Enrolled in Two Clinical Trials Using Embryonic Stem Cells to Treat Stargardt’s and Macular Degeneration

Thursday, June 16, 2011 By: Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived

ACT Names Test Sites for Stargardt’s Macular Dystrophy Therapy

Monday, May 16, 2011 By: Advanced Cell Technology Inc. Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) in Portland, Ore., has received institutional review board (IRB) approval to be a site for its Phase 1/2 human

ACT Files European Clinical Trial Application For Phase 1/2 Study Using Embryonic Stem Cells To Treat Macular Degeneration

Thursday, April 21, 2011 By: Medical News Today Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE)

Stem Cell Trial Sets Sight on Blindness

Monday, January 10, 2011 By: Jill U. Adams, Los Angeles Times The FDA has OKd a new study aimed at fighting age-related macular degeneration. About 10 million Americans suffer some degree of vision loss caused by age-related macular degeneration, and that figure is expected to grow as more baby boomers become senior citizens. There is

Human Embryonic Stem Cells May Help Older People Battle Blindness

Monday, January 3, 2011 By: Karen Kaplan, Los Angeles Times A therapy derived from human embryonic stem cells may help millions of Americans battle a common form of blindness. Advanced Cell Technology Inc. said Monday that it has received a green light from the U.S. Food and Drug Administration to begin a clinical trial to